cognitive cybersecurity intelligence

News and Analysis

Search

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim

ArriVent Biopharma paid $47m to license MRG007, a Phase 1-ready gastrointestinal cancer therapy developed by Shanghai’s Lepu Biopharma. The antibody drug conjugate has not had its target disclosed but ArriVent said studies showed it had “best-in-class potential”, and suggested it could be a drug that targets claudin 18.2. ArriVent said MRG007 displayed strong anti-tumour action in preclinical models, with the first submissions expected in H1 2022.

Source: medcitynews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Secure all devices for under $16

Mashable is promoting an AdGuard family plan deal that secures up to nine devices for a lifetime for $15.97. AdGuard provides protection from harmful ads

10 Best Free Blue Team Tools in 2025

Companies enhance their cybersecurity through assessments by employing “red teams” for offensive testing and “blue teams” for defense. Blue teams focus on protecting assets, conducting